MX2022015629A - Uso de vibegron para tratar vejiga sobreactiva. - Google Patents

Uso de vibegron para tratar vejiga sobreactiva.

Info

Publication number
MX2022015629A
MX2022015629A MX2022015629A MX2022015629A MX2022015629A MX 2022015629 A MX2022015629 A MX 2022015629A MX 2022015629 A MX2022015629 A MX 2022015629A MX 2022015629 A MX2022015629 A MX 2022015629A MX 2022015629 A MX2022015629 A MX 2022015629A
Authority
MX
Mexico
Prior art keywords
vibegron
overactive bladder
treat overactive
directed
present disclosure
Prior art date
Application number
MX2022015629A
Other languages
English (en)
Inventor
Stephen C Piscitelli
Paul Mudd
Original Assignee
Urovant Sciences Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Urovant Sciences Gmbh filed Critical Urovant Sciences Gmbh
Publication of MX2022015629A publication Critical patent/MX2022015629A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder

Abstract

La presente divulgación se refiere a un método de tratamiento de vejiga sobreactiva que comprende administrar por vía oral a un sujeto que lo necesita una cantidad de desde aproximadamente 60 mg hasta aproximadamente 90 mg (por ejemplo, aproximadamente 75 mg) de vibegron al día. La presente divulgación también se refiere a una composición de dosificación unitaria farmacéutica que comprende desde aproximadamente 60 mg hasta aproximadamente 90 mg (por ejemplo, aproximadamente 75 mg) de vibegron para administración oral.
MX2022015629A 2017-06-06 2019-12-04 Uso de vibegron para tratar vejiga sobreactiva. MX2022015629A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762515996P 2017-06-06 2017-06-06
US201862635146P 2018-02-26 2018-02-26
US201862637961P 2018-03-02 2018-03-02

Publications (1)

Publication Number Publication Date
MX2022015629A true MX2022015629A (es) 2023-01-11

Family

ID=62815097

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022015629A MX2022015629A (es) 2017-06-06 2019-12-04 Uso de vibegron para tratar vejiga sobreactiva.

Country Status (13)

Country Link
US (1) US20210077495A1 (es)
EP (1) EP3634420A1 (es)
JP (2) JP2020522560A (es)
KR (1) KR20200012949A (es)
CN (3) CN117695286A (es)
AU (1) AU2018282104A1 (es)
BR (1) BR112019025636A2 (es)
CA (1) CA3064989A1 (es)
CL (1) CL2019003533A1 (es)
IL (1) IL271164A (es)
MX (1) MX2022015629A (es)
PH (1) PH12019502651A1 (es)
WO (1) WO2018224989A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3730141A4 (en) * 2017-12-21 2021-10-13 Kyorin Pharmaceutical Co., Ltd. THERAPEUTIC FOR NIGHTLY POLLAKISURIA
TW202038963A (zh) * 2018-12-05 2020-11-01 瑞士商優洛凡特科學公司 維貝隆（ｖｉｂｅｇｒｏｎ）於治療患有良性***增生之男性中膀胱過動症症狀之用途
CN113840607A (zh) 2019-03-18 2021-12-24 尤偌万科学有限公司 维贝格龙治疗膀胱过度活动症的用途
DE102020124101A1 (de) 2020-02-04 2021-08-05 Samsung Electronics Co., Ltd. Elektronische vorrichtung mit einer speichervorrichtung und trainingsverfahren
IL303911A (en) 2020-12-22 2023-08-01 Urovant Sciences Gmbh Methods for dioxin monitoring using Vibergon to treat irritable bladder

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0015246D0 (en) * 2000-06-22 2000-08-16 Astrazeneca Ab Method for the treatment of urinary incontinence
PE20091825A1 (es) 2008-04-04 2009-12-04 Merck & Co Inc Hidroximetil pirrolidinas como agonistas del receptor adrenergico beta 3
ES2584427T3 (es) 2011-10-27 2016-09-27 Merck Sharp & Dohme Corp. Proceso para la preparación de agonistas beta 3 y productos intermedios
WO2013062881A1 (en) 2011-10-27 2013-05-02 Merck Sharp & Dohme Corp. Process for making beta 3 agonists and intermediates
UA112028C2 (uk) * 2012-12-14 2016-07-11 Пфайзер Лімітед Похідні імідазопіридазину як модулятори гамка-рецептора
DK2968269T3 (da) 2013-03-15 2019-10-07 Merck Sharp & Dohme Fremgangsmåde til fremstilling af beta-3-agonister og mellemprodukter

Also Published As

Publication number Publication date
CN117695286A (zh) 2024-03-15
BR112019025636A2 (pt) 2020-08-25
AU2018282104A1 (en) 2019-12-12
IL271164A (en) 2020-01-30
CA3064989A1 (en) 2018-12-13
KR20200012949A (ko) 2020-02-05
CN110869022A (zh) 2020-03-06
PH12019502651A1 (en) 2020-06-08
WO2018224989A1 (en) 2018-12-13
US20210077495A1 (en) 2021-03-18
JP2020522560A (ja) 2020-07-30
CL2019003533A1 (es) 2020-06-26
CN117695287A (zh) 2024-03-15
EP3634420A1 (en) 2020-04-15
JP2023071826A (ja) 2023-05-23

Similar Documents

Publication Publication Date Title
MX2022015629A (es) Uso de vibegron para tratar vejiga sobreactiva.
PH12015502691A1 (en) Use of high dose pridopidine for treating huntington's disease
MX2022003072A (es) Uso de pridopidina para el tratamiento de la disminucion funcional.
MX2020008258A (es) Formulaciones pediátricas de niraparib y métodos de tratamiento pediátricos.
MX2019012884A (es) Terapia de combinacion.
EA201492010A1 (ru) Применение высокой дозы лахинимода для лечения рассеянного склероза
MX2023000187A (es) Dosificacion de vibegron para el tratamiento de vejiga sobreactiva.
RU2017116740A (ru) Комбинации для лечения рассеянного склероза
PH12020500543A1 (en) Nonracemic mixtures and uses thereof
SG10201810404XA (en) Combination comprising a glucocorticoid and edo-s101
MA39765A (fr) Formulation pharmaceutique d'un inhibiteur de la kinase pan-raf, ses procédés de préparation, et procédés d'utilisation
BR112019002461A2 (pt) regime de dosagem para tratamento de tumores sólidos
MX2021000363A (es) Uso de estimuladores de la guanilato ciclasa soluble (sgc) para el tratamiento de trastornos mitocondriales.
MX2020012377A (es) Uso de tabletas de desintegracion orales de riluzol para el tratamiento de enfermedades.
MX2021002322A (es) Nuevos metodos.
NZ751972A (en) Treatment of prurigo nodularis
MX2020013692A (es) Compuestos de pirazol e imidazol para la inhibicion de il-17 y rorgamma.
MY193963A (en) Composition for treating joint diseases and kit containing same
MX2023002649A (es) Nueva formulacion de acido gamma-aminobutirico.
IL250852B (en) Periodontal preparation
MX2021007324A (es) Terapia oral con acido 6,8-bis-benciltio-octanoico.
EA202090416A1 (ru) Способы лечения симптомов гастропареза с использованием велусетрага
MX2021004138A (es) Metodos y formulaciones para tratar nauseas y vomito inducidos por quimioterapias.
EA201992690A1 (ru) Применение вибегрона для лечения гиперактивного мочевого пузыря
RU2013126798A (ru) Комбинированная терапия дексаметазоном